ArticleCureus2025
Advanced Melanoma Management: A Case Report of Pembrolizumab Use in a Haemodialysis Patient.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Patients with end-stage renal disease are a challenge for oncologists. Despite the recognised benefit in the overall survival of pembrolizumab in patients with advanced melanoma, data on its safety and efficacy in dialysis patients are scarce. We present a clinical case of an 87-year-old woman on haemodialysis with advanced melanoma treated in the first line with pembrolizumab 200 mg every three weeks. She shows no significant adverse events and a good response to treatment. Although she underwent surgical treatment for two oligoprogressions, the patient maintained treatment with pembrolizumab, now demonstrating a response duration of 20 months. The age and comorbidities in this case, coupled with the lack of robust scientific evidence on the use of immunotherapy in dialysis patients, illustrate the daily complexity of therapeutic decisions in oncology.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.